Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TNIK_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TNIK_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TNIK_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TNIK_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TNIK_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TNIK_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:01987381 | Colorectum | SER | cell-cell signaling by wnt | 97/2897 | 446/18723 | 2.39e-04 | 4.11e-03 | 97 |
GO:00163581 | Colorectum | SER | dendrite development | 58/2897 | 243/18723 | 3.82e-04 | 5.81e-03 | 58 |
GO:00315321 | Colorectum | SER | actin cytoskeleton reorganization | 30/2897 | 107/18723 | 6.38e-04 | 8.64e-03 | 30 |
GO:00109751 | Colorectum | SER | regulation of neuron projection development | 92/2897 | 445/18723 | 1.85e-03 | 1.89e-02 | 92 |
GO:0048813 | Colorectum | SER | dendrite morphogenesis | 36/2897 | 146/18723 | 2.51e-03 | 2.33e-02 | 36 |
GO:0050773 | Colorectum | SER | regulation of dendrite development | 27/2897 | 103/18723 | 3.35e-03 | 2.86e-02 | 27 |
GO:00310981 | Colorectum | SER | stress-activated protein kinase signaling cascade | 54/2897 | 247/18723 | 4.65e-03 | 3.67e-02 | 54 |
GO:00514031 | Colorectum | SER | stress-activated MAPK cascade | 52/2897 | 239/18723 | 5.96e-03 | 4.35e-02 | 52 |
GO:00726592 | Colorectum | MSS | protein localization to plasma membrane | 113/3467 | 284/18723 | 3.23e-17 | 1.55e-14 | 113 |
GO:19907782 | Colorectum | MSS | protein localization to cell periphery | 120/3467 | 333/18723 | 2.02e-14 | 5.47e-12 | 120 |
GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
GO:00315322 | Colorectum | MSS | actin cytoskeleton reorganization | 41/3467 | 107/18723 | 1.21e-06 | 4.06e-05 | 41 |
GO:00109752 | Colorectum | MSS | regulation of neuron projection development | 115/3467 | 445/18723 | 6.91e-05 | 1.20e-03 | 115 |
GO:00325282 | Colorectum | MSS | microvillus organization | 13/3467 | 24/18723 | 9.44e-05 | 1.49e-03 | 13 |
GO:00467772 | Colorectum | MSS | protein autophosphorylation | 63/3467 | 227/18723 | 3.96e-04 | 4.91e-03 | 63 |
GO:00310982 | Colorectum | MSS | stress-activated protein kinase signaling cascade | 67/3467 | 247/18723 | 5.28e-04 | 5.99e-03 | 67 |
GO:00514032 | Colorectum | MSS | stress-activated MAPK cascade | 65/3467 | 239/18723 | 5.87e-04 | 6.49e-03 | 65 |
GO:00300332 | Colorectum | MSS | microvillus assembly | 9/3467 | 16/18723 | 8.20e-04 | 8.59e-03 | 9 |
GO:00163582 | Colorectum | MSS | dendrite development | 65/3467 | 243/18723 | 9.41e-04 | 9.50e-03 | 65 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNIK | SNV | Missense_Mutation | novel | c.664N>C | p.Thr222Pro | p.T222P | Q9UKE5 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNIK | SNV | Missense_Mutation | novel | c.1642N>C | p.Ser548Pro | p.S548P | Q9UKE5 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TNIK | SNV | Missense_Mutation | | c.335N>G | p.Ser112Cys | p.S112C | Q9UKE5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TNIK | SNV | Missense_Mutation | | c.1679N>T | p.Ser560Phe | p.S560F | Q9UKE5 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.887) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNIK | SNV | Missense_Mutation | novel | c.1642N>C | p.Ser548Pro | p.S548P | Q9UKE5 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
TNIK | SNV | Missense_Mutation | novel | c.1201N>G | p.Gln401Glu | p.Q401E | Q9UKE5 | protein_coding | tolerated(0.22) | possibly_damaging(0.68) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
TNIK | SNV | Missense_Mutation | rs867347961 | c.3086N>G | p.Asn1029Ser | p.N1029S | Q9UKE5 | protein_coding | tolerated(0.08) | benign(0.325) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
TNIK | SNV | Missense_Mutation | novel | c.664A>C | p.Thr222Pro | p.T222P | Q9UKE5 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNIK | SNV | Missense_Mutation | | c.1763N>C | p.Val588Ala | p.V588A | Q9UKE5 | protein_coding | deleterious(0.04) | benign(0.074) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNIK | SNV | Missense_Mutation | | c.1714N>C | p.Ser572Arg | p.S572R | Q9UKE5 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.791) | TCGA-C8-A1HN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23043 | TNIK | ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | | SB-202190 | SB-202190 | 22951114 |
23043 | TNIK | ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
23043 | TNIK | ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 135652717 | STAUROSPORINE | |
23043 | TNIK | ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | inhibitor | 249565872 | | |
23043 | TNIK | ENZYME, DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE | | CEP-1347 | CEP-1347 | 24044867 |